Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Data from the Phase 3 EV-303 trial found that enfortumab vedotin plus pembrolizumab showed a 60% reduction in the risk of disease recurrence, progression or death, and a 50% reduction in the...
TOKYO, January 7, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference,...
Read more about Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
- Pioneering cell therapy innovation through robotics and AI - - Among the first innovator pharmaceutical companies granted AMT designation - - Enabling early, priority engagement with FDA to...
PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients...
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in...
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the...
TOKYO, November 28, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) validated for review a Type...
- PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible...
Read more about U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
TOKYO, October 30, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced revisions to its consolidated financial forecast for the fiscal year...
Read more about Notice Regarding Revision of Financial Forecasts for FY2025
Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational...
Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by...
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found...
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to...
TOKYO, October 14, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the Phase 2 GLEAM trial investigating zolbetuximab in combination...
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025...
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi,...
Read more about Astellas Announces Top Management Personnel Change
TOKYO, Sep 19, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has...
NEW YORK AND TOKYO, August 12, 2025 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from...
- Supporting Korean Startups’ Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO, July 17, 2025 –...
TOKYO, July 10, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the sales in the U.S. of the IZERVAY™ (avacincaptad pegol...
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan Tokyo, 13 June 2025—Mitsubishi Research Institute, Inc. (“MRI”) and Astellas Pharma Inc. (“Astellas”) today...
- Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated...
Follow us
